The financing was led by EMV Capital Partners and will support operational scaling and early customer deployments.
"We are pleased to have secured this significant investment from our existing shareholder base, and to welcome NSSIF as a new strategic shareholder. This support is a testament to the disruptive potential of Sofant’s technology and the remarkable progress our team has made in recent months. With this additional capital, we are positioned to accelerate our commercial deployment and redefine what is possible in wireless communications."
River Capital led the EIS funding round, which included backing from EHE Ventures.
"For years, companies have had access to every possible metric about their competitors – except the ones that matter most. Financials and customer metrics are easy to map, but understanding how organisations lead, retain, and inspire people has always been the missing piece. Deltabase fills that gap. We give decision-makers actionable, data-backed evidence of how teams operate, so they can move faster and with more confidence. When you bring clarity to culture, you change how strategy gets delivered."
The funding round was led by 645 Ventures and will be used to accelerate product development and team expansion.
"I started Sequence afiter a decade watching fiinance teams fiace an impossible choice: drown in manual billing work or rely on systems that break when sales teams close custom deals. Hereʼs whatʼs happening in fiinance teams – brilliant people spend 80% ofi their time on repetitive tasks like calculating invoices by hand, chasing unpaid bills, and reconciling transactions, while revenue slips through the cracks because complex contracts are hard to track. Sales shouldnʼt be constrained by what the billing engine can support. With Sequence, teams can price and sell in the way thatʼs best fior customers and the business, while Finance has peace ofi mind knowing every contract, no matter how custom, is handled accurately."
The funding round will support the development of hospital-ready diagnostic products and broaden clinical access to glycan testing.
"Together with genetics, the concept of personalised medicine requires a dynamic approach. Genomics provides the blueprint of where we begin, but health is not static—it evolves with time, environment, and lifestyle. To truly transform care, we must complement genomic insights with modifiable biomarkers: biological signals that capture real-time responses to interventions and track improvement longitudinally. This synergy between genomics and adaptive biomarkers is the cornerstone for turning personalised medicine from a descriptive concept into actionable, measurable, and preventative healthcare."
.png)
